Sign in
Taking people in United StatesPhase 2

Liver-directed melphalan followed by tebentafusp for uveal melanoma that has spread to the liver

Tests melphalan delivered to the liver, then tebentafusp, in metastatic uveal melanoma.

Key facts

Who runs it
H. Lee Moffitt Cancer Center and Research Institute
Where
Tampa, United StatesSee the site
Trial code
Registry title
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Status
Recruiting
Phase
Phase 2
People taking part
18 people, planned
Started
31 Dec 2025
Expected to end
Dec 2030
Type of study
Interventional
Treatments tested
  • Melphalan/HDS (Percutaneous Hepatic Perfusion)
  • Tebentafusp
Record updated
31 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with uveal melanoma that has spread to the liver. People get liver perfusion with melphalan/HDS, then tebentafusp.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Uveal melanoma with liver metastases confirmed by tissue or cell tests. At least one measurable tumor in the liver on CT. Limited spread outside the liver is allowed at first if it can be treated with SBRT or surgery before tebentafusp.
Earlier treatment
People who had earlier PHP or tebentafusp cannot join.
Biomarker or test result
HLA-A*02:01 positive. ECOG performance status of 0 or 1.

Main reasons for not taking part

  • Life expectancy of less than 6 months
  • More than 50% of the liver volume replaced by tumor
  • Known HIV, AIDS, hepatitis B or hepatitis C
  • Active autoimmune disease, or treatment that weakens the immune system
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Patient is ≥18 years of age on the day of signing informed consent
  • ECOG performance status of 0 or 1
  • Histologically or cytologically confirmed liver metastasis of uveal melanoma
  • HLA-A*02:01 positive status
  • Measurable disease by computed tomography (CT) per RECIST 1.1 with at least one target lesion identified in the liver
  • Patient deemed suitable for PHP and tebentafusp
  • Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Female patients of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 150 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
  • Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 150 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
  • Limited extrahepatic disease would be allowed initially, that can be treated with stereotactic body radiation therapy (SBRT) or surgical resection prior to the start of tebentafusp. This concept is similar to the FOCUS trial - definition of "treatable" limited disease at the discretion of the PI
  • Ability to provide and understand written informed consent prior to any study procedures

Who cannot take part

  • Use of live vaccines four weeks before the last study treatment
  • History of severe reactions to melphalan, heparin or iodine contrast. Iodine contrast reaction history patients permitted if patient will be treated with pre-meds, or if still problematic, treating physician may switch to MRI TAP
  • A condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Concomitant therapy with any other anti-cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications (other than physiologic (i.e., >10 mg) doses of steroids or as specified in exclusion #14) or use of other investigational drugs
  • Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of study drug
  • Previous treatment with PHP or tebentafusp
  • Extrahepatic disease as measured by CT of thorax abdomen and pelvis. (See inclusion criteria #10 above for limited treatable extrahepatic disease.)
  • History of congestive heart failure, active cardiac conditions, including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), significant arrhythmias and severe valvular disease that precludes the use of general anesthesia
  • History or evidence of clinically significant pulmonary disease e.g. severe COPD that precludes the use of general anesthesia
  • Known human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C
  • Active autoimmune disease or a documented history of autoimmune disease requiring active systemic immunosuppressive treatment. Type-1 diabetes, atopic dermatitis, and hypothyroidism are exceptions to this
  • Has a known additional malignancy that is progressing or requires active treatment
  • Reduced renal function defined as Serum Creatinine >=1.5xULN or Creatinine Clearance < 40 mL/min, calculated using the Cockcroft and Gault formula
  • Reduced hepatic function (defined as AST, ALT, bilirubin>2.5*ULN and PT-INR>1.5) or medical history of liver cirrhosis (Child-Pugh Class B or C) or evidence of portal hypertension by history, endoscopy or radiology
  • Hemoglobin <90 g/L or platelets <100x109/L or neutrophils <1.5x109/L
  • A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate in the opinion of the treating investigator
  • Life expectancy of less than 6 months
  • More than 50% of the liver volume replaced by tumor as measured by MRI
  • Patients who are unable to undergo general anesthesia for any reason

Where in United States

  • Moffitt Cancer CenterTampa, United StatesContact: Jonathan Zager, MD, FACS (principal investigator)Taking people

About the trial

What the trial wants to find out

This Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances antigen release and immunomodulation, potentially sensitizing tumors to tebentafusp in HLA-A*02:01-positive patients.

The group in the trial

  • Sequential PHP with Melphalan/HDS followed by TebentafuspTreatment being tested

    Patients will undergo two percutaneous hepatic perfusion (PHP) procedures with melphalan/HDS, spaced 6-8 weeks apart. Tebentafusp will be initiated within 6 weeks (+/- 2 weeks) after the second PHP and administered weekly for 1 year. Additional PHP procedures (up to 6 total) may be performed as standard of care if disease progression occurs while on tebentafusp.

    Treatment: Melphalan/HDS (Percutaneous Hepatic Perfusion) and Tebentafusp

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase 2 Sequential Treatment With Melphalan/HDS Via Percutaneous Hepatic Perfusion Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma
Plain-language title
Liver-directed melphalan followed by tebentafusp for uveal melanoma that has spread to the liverGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
31 March 2026